India, Sept. 27 -- Milestone Pharmaceuticals Inc. (MIST), a biopharmaceutical company, on Friday announced the enrollment of the first patient in the Canadian site of the Phase 3 ReVeRA-301 trial evaluating the Etripamil nasal spray for treating atrial fibrillation with rapid ventricular rate (AFib-RVR). Etripamil received approval from the U.S. Food and Drug Administration (FDA) in December 2025 and is marketed in the country as CARBAMYST. The drug is formulated as a nasal spray for treating Paroxysmal Supraventricular Tachycardia (PSVT), and was made available in retail pharmacies in January 2026, with a national sales force launched in February. A Marketing Authorization Approval (MAA) for the drug is expected from the European Medicines...